WP07 Neurophysiologic and QoL


 

Work Package Lead: Prof. Michael Brainin

07. UNIVERSITAET FUER WEITERBILDUNG KREMS – DUK (AT)

 

Objectives:

  • Assess neuropsychological profiles and Quality of Life in persons with hyperglycemia.
  • Identify assessment tools suited for testing of cognition.
  • Coordinate data on psychopathological profiles, peripheral neuropathy symptoms and sleep disturbances.
  • Coordinate data handling and data evaluation.

 

Main tasks:
1. Assessment instruments for cognition and quality of life:

  • Assessment of cognition has to be sensitive enough to detect not only manifest dementia but also mild cognitive impairment and clinically less significant decline in different cognitive domains such as executive functions, speed of cognitive processing and working memory. To evaluate, discuss and select a package of assessment tools, a workshop will be held in Austria. The workshop will bring together clinicians, neuropsychologists and other experts of the consortium with the aim to select a set of validated and highly language independent neuropsychological tests appropriate for the study population. A final neuropsychological test battery will then be recommended for use to all participating centres.
  • Extended measures for Quality of Life include depression, peripheral neuropathy symptoms (pain) and sleeping disorders. Obstructive sleep apnea will be detected by nocturnal cardio-respiratory monitoring at home; study parameters being the apnea-hypopnea –index, sleeping positions, oxygen saturation and heart rate (partner #31). Previously validated sleep questionnaires will be used to screen for the intensity of snoring and daytime sleepiness. Emotional changes over time will be evaluated by appropriate questionnaires for anxiety and depression and anxiety (Hamilton scores) questionnaire(partner 27) . New cases of depression and anxiety will be also detected using the WHO-MINI (Mini International Neuropsychiatric Interview) questionnaire.
  • Neuropathy will be evaluated by the sweating function index as measured by SUDOSCAN from Impeto (Parnter 30), and will be part of the primary outcome. IMPETO will be responsible for the training and certification in the use of the device.
  • Assessment tools will be adapted if necessary. Standard operating procedures will be defined from the responsible centre and instruction manuals will be distributed to the recruiting centres.

2. Data handling and transfer of collected data:

  • The results of the neuropsychological test battery and the Quality of Life assessments will be collected and summarised in a central data base (supported and coordinated by partner #9). Therefore the responsible centres will deliver data templates that are standardized. To ensure the quality of the data base, data will be checked for consistency and accuracy.
  • The summarised data will be made available to the experts of WP8 for extended statistical analysis.

 

Scroll to Top